The Effects of Antifracture Therapies on the Components of Bone Strength: Assessment of Fracture Risk Today and in the Future

Seminars in Arthritis and Rheumatism

Volumn 36, Issue 1, 2006, Pages 10-21

  Davison, K Shawn ^a   Siminoski, Kerry ^b   Adachi, J D ^c   Hanley, David A ^d   Goltzman, David ^e   Hodsman, Anthony B ^f   Josse, Robert ^g   Kaiser, Stephanie ^h   Olszynski, Wojciech P ⁱ   Papaioannou, Alexandra ^j   Ste Marie, Louis George ^k   Kendler, David L ^l   Tenenhouse, Alan ^e   Brown, Jacques P ^m  

^a UNIVERSITÉ LAVAL   (Canada)

^b Division of Endocrinology and Metabolism   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e MCGILL UNIVERSITY   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ UNIVERSITY OF SASKATCHEWAN   (Canada)

^j MCMASTER UNIVERSITY   (Canada)

^k UNIVERSITY OF MONTREAL   (Canada)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m LAVAL UNIVERSITY   (Canada)

more..

Author keywords

architecture; bisphosphonates; bone; mineralization; parathyroid hormone therapy; remodeling; risk factors; strength

Indexed keywords

ALENDRONIC ACID; BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLLAGEN; CONJUGATED ESTROGEN; ESTROGEN; ETIDRONIC ACID; FLUORIDE; ORGANIC MATTER; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SOMATOMEDIN C; STRONTIUM RANELATE; ZOLEDRONIC ACID;

AGE; ANISOTROPY; ARTICLE; BONE DENSITY; BONE FRAGILITY; BONE INJURY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE STRESS; BONE STRUCTURE; BONE TISSUE; BONE TURNOVER; CLINICAL TRIAL; CRYSTALLIZATION; DRUG EFFECT; DRUG EFFICACY; ESTROGEN THERAPY; FRACTURE TREATMENT; FRAGILITY FRACTURE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; MEDLINE; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAGET BONE DISEASE; POROSITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; THERAPY; WEAKNESS;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; FRACTURES, SPONTANEOUS; HUMANS; RISK FACTORS;

EID: 33746601823     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2006.04.001     Document Type: Article

References (91)

1. Meunier P.J., and Boivin G. Bone mineral density reflects bone mass but also the degree of mineralization of bone. therapeutic implications. Bone 21 (1997) 373-377
2. Kneissel M., Boyde A., and Gasser J.A. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone 28 (2001) 237-250
3. Camacho N.P., Rinnerthaler S., Paschalis E.P., Mendelsohn R., Boskey A.L., and Fratzl P. Complementary information on bone ultrastructure from scanning small angle X-ray scattering and Fourier-transform infrared microspectroscopy. Bone 25 (1999) 287-293
4. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., and Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 (2001) 185-191
5. Evans R.A., Dunstan C.R., Hills E., and Wong S.Y. Pathologic fracture due to severe osteomalacia following low-dose diphosphonate treatment of Paget's disease of bone. Aust NZ J Med 13 (1983) 277-279
6. Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Does suppression of bone turnover impair mechanical properties by allowing microdamage accumulation?. Bone 27 (2000) 13-20
7. Nuzzo S., Lafage-Proust M.H., Martin-Badosa E., Boivin G., Thomas T., Alexandre C., et al. Synchrotron radiation microtomography allows the analysis of three-dimensional microarchitecture and degree of mineralization of human iliac crest biopsy specimens. effects of etidronate treatment. J Bone Miner Res 17 (2002) 1372-1382
8. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687-694
9. Boivin G., and Meunier P.J. Effects of bisphosphonates on matrix mineralization. J Musculoskel Neuron Interact 2 (2002) 538-543
10. Roschger P., Gupta H.S., Berzlanovich A., Ittner G., Dempster D.W., Fratzl P., et al. Constant mineralization density distribution in cancellous human bone. Bone 32 (2003) 316-323
11. Eriksen E.F., Melsen F., Sod E., Barton I., and Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone 31 (2002) 620-625
12. Harris S.T., Watts N.B., Genant H.K., McKeever C.D., Hangartner T., Keller M., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. a randomized controlled trial. JAMA 282 (1999) 1344-1352
13. Ritman E.L., Borah B., Dufresne R.J., Phipps R.J., Sacha J.P., Jorgensen S.M., et al. 3-D synchrotron micro-CT allows unique insight of changes in bone quality with risedronate therapy. Calcif Tissue Int 72 (2003) 202
14. Borah B., Ritman E.L., Dufresne R.J., Liu S., Chmielewski P.A., Jorgensen S.M., et al. Five year risedronate therapy normalizes mineralization. synchrotron radiation micro-computed tomography study of sequential triple biopsies. J Bone Miner Res 19 (2004) S308
15. Boivin G., Arlot M.E., Trechsel U., and Meunie P.J. Effects of intravenous zoledronic acid on the degree of mineralization of bone in postmenopausal osteoporosis. a quantitative microradiographic analysis of transiliac biopsies after one year. J Bone Miner Res 18 (2003) S261
16. Arlot M.E., Roux J.P., Portero N., Horowitz Z., Richardson P., Trechsel U., et al. Effects of intravenous zoledronic acid on bone remodeling in postmenopausal osteoporosis. a histomorphometric analysis of transilliac biopsies after one year. J Bone Miner Res 16 (2001) S284
17. Boivin G., Lips P., Ott S.M., Harper K.D., Sarkar S., Pinette K.V., et al. Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88 (2003) 4199-4205
18. Misof B.M., Roschger P., Cosman F., Kurland E.S., Tesch W., Messmer P., et al. Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis. a paired study before and after treatment. J Clin Endocrinol Metab 88 (2003) 1150-1156
19. Boskey A.L. Bone mineral crystal size. Osteoporos Int 14 (2003) S16-S21
20. Eanes E.D., and Hailer A.W. The effect of fluoride on the size and morphology of apatite crystals grown from physiologic solutions. Calcif Tissue Int 63 (1998) 250-257
21. Sogaard C.H., Mosekilde L., Richards A., and Mosekilde L. Marked decrease in trabecular bone quality after five years of sodium fluoride therapy-assessed by biomechanical testing of iliac crest bone biopsies in osteoporotic patients. Bone 15 (1994) 393-399
22. Paschalis E.P., Boskey A.L., Kassem M., and Eriksen E.F. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res 18 (2003) 955-959
23. Anderson G.L., Limacher M., Assaf A.R., Bassford T., Beresford S.A., Black H., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. the Women's Health Initiative randomized controlled trial. JAMA 291 (2004) 1701-1712
24. Paschalis E.P., and Phipps R. Three-years treatment with risedronate preserves bone quality. Calcif Tissue Int 72 (2003) 212
25. Boivin G., and Meunier P.J. The mineralization of bone tissue. a forgotten dimension in osteoporosis research. Osteoporos Int 14 suppl 3 (2003) S19-S24
26. Hyldstrup L., Jorgensen J.T., Sorensen T.K., and Baeksgaard L. Response of cortical bone to antiresorptive treatment. Calcif Tissue Int 68 (2001) 135-139
27. Dufresne T.E., Chmielewski P.A., Manhart M.D., Johnson T.D., and Borah B. Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography. Calcif Tissue Int 73 (2003) 423-432
28. Andreassen T.T., Jorgensen P.H., Flyvbjerg A., Orskov H., and Oxlund H. Growth hormone stimulates bone formation and strength of cortical bone in aged rats. J Bone Miner Res 10 (1995) 1057-1067
29. Jorgensen P.H., Bak B., and Andreassen T.T. Mechanical properties and biochemical composition of rat cortical femur and tibia after long-term treatment with biosynthetic human growth hormone. Bone 12 (1991) 353-359
30. Oxlund H., Ejersted C., Andreassen T.T., Torring O., and Nilsson M.H. Parathyroid hormone (1-34) and (1-84) stimulate cortical bone formation both from periosteum and endosteum. Calcif Tissue Int 53 (1993) 394-399
31. Toromanoff A., Ammann P., and Riond J.L. Early effects of short-term parathyroid hormone administration on bone mass, mineral content, and strength in female rats. Bone 22 (1998) 217-223
32. Turner C.H., and Burr D.B. Basic biomechanical measurements of bone. a tutorial. Bone 14 (1993) 595-608
33. Sato M., Westmore M., Ma Y.L., Schmidt A., Zeng Q.Q., Glass E.V., et al. Teriparatide [PTH(1-34)] strengthens the proximal femur of ovariectomized nonhuman primates despite increasing porosity. J Bone Miner Res 19 (2004) 623-629
34. Cummings S.R. How drugs decrease fracture risk. J Musculoskel Neuron Interact 2 (2002) 198-200
35. Borah B., Dufresne T.E., Chmielewski P.A., Johnson T.D., Chines A., and Manhart M.D. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34 (2004) 736-746
36. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis. a paired biopsy study. J Bone Miner Res 16 (2001) 1846-1853
37. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A., Reginster J.Y., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
38. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15 (2000) 613-620
39. Mashiba T., Turner C.H., Hirano T., Forwood M.R., Johnston C.C., and Burr D.B. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28 (2001) 524-531
40. Norman T.L., Yeni Y.N., Brown C.U., and Wang Z. Influence of microdamage on fracture toughness of the human femur and tibia. Bone 23 (1998) 303-306
41. Plotkin L.I., Weinstein R.S., Parfitt A.M., Roberson P.K., Manolagas S.C., and Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104 (1999) 1363-1374
42. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., and Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104 (1999) 439-446
43. Mori S., Harruff R., Ambrosius W., and Burr D.B. Trabecular bone volume and microdamage accumulation in the femoral heads of women with and without femoral neck fractures. Bone 21 (1997) 521-526
44. Flora L., Hassing G.S., Cloyd G.G., Bevan J.A., Parfitt A.M., and Villanueva A.R. The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res 3 (1981) 289-300
45. Lenehan T.M., Balligand M., Nunamaker D.M., and Wood Jr. F.E. Effect of EHDP on fracture healing in dogs. J Orthop Res 3 (1985) 499-507
46. Johnston Jr. C.C., Altman R.D., Canfield R.E., Finerman G.A., Taulbee J.D., and Ebert M.L. Review of fracture experience during treatment of Paget's disease of bone with etidronate disodium (EHDP). Clin Orthop (1983) 186-194
47. Mautalen C., Gonzalez D., Blumenfeld E.L., Santini A.E., and Schajowicz F. Spontaneous fractures of uninvolved bones in patients with Paget's disease during unduly prolonged treatment with disodium etidronate (EHDP). Clin Orthop (1986) 150-155
48. Gibbs C.J., Aaron J.E., and Peacock M. Osteomalacia in Paget's disease treated with short term, high dose sodium etidronate. Br Med J 292 (1986) 1227-1229
49. Li J., Mashiba T., and Burr D.B. Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage. Calcif Tissue Int 69 (2001) 281-286
50. Roux C., Seeman E., Eastell R., Adachi J., Jackson R.D., Felsenberg D., et al. Efficacy of risedronate on clinical vertebral fractures within six months. Curr Med Res Opin 20 (2004) 433-439
51. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112 (2002) 281-289
52. Boyce B.F., Smith L., Fogelman I., Johnston E., Ralston S., and Boyle I.T. Focal osteomalacia due to low-dose diphosphonate therapy in Paget's disease. Lancet 1 8381 (1984) 821-824 Apr 14;
53. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., and Hock J.M. Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res 16 (2001) 157-165
54. Boivin G., and Meunier P.J. The degree of mineralization of bone tissue measured by computerized quantitative contact microradiography. Calcif Tissue Int 70 (2002) 503-511
55. Miller P.D., Siris E.S., Barrett-Connor E., Faulkner K.G., Wehren L.E., Abbott T.A., et al. Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry. evidence from the National Osteoporosis Risk Assessment. J Bone Miner Res 17 (2002) 2222-2230
56. van Staa T.P., Leufkens H.G., and Cooper C. The epidemiology of corticosteroid-induced osteoporosis. a meta-analysis. Osteoporos Int 13 (2002) 777-787
57. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., and Jonsson B. Ten year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12 (2001) 989-995
58. Black D.M., Cummings S.R., Karpf D.B., Cauley J.A., Thompson D.E., Nevitt M.C., et al., Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
59. Pols H.A.P. A multinational, placebo-controlled, randomized study of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass. results of the FOSIT Study. Osteoporos Int 9 (1999) 461-468
60. Watts N.B., Josse R.G., Hamdy R.C., Hughes R.A., Manhart M.D., Barton I., et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 88 (2003) 542-549
61. Cranney A., Wells G., Willan A., Griffith L., Zytaruk N., Robinson V., et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23 (2002) 508-516
62. Cranney A., Tugwell P., Zytaruk N., Robinson V., Weaver B., Adachi J., et al. Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal. osteoporosis. Endocr Rev 23 (2002) 524-528
63. Cranney A., Tugwell P., Adachi J., Weaver B., Zytaruk N., Papaioannou A., et al. Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23 (2002) 517-523
64. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelsen T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. results from a 3-year randomized clinical trial. J Am Med Assoc 282 (1999) 637-645
65. Chesnut III C.H., Silverman S., Andriano K., Genant H., Gimona A., Harris S., et al., PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis. the prevent recurrence of osteoporotic fractures study. Am J Med 109 (2000) 267-276
66. Watts N.B., Cooper C., Lindsay R., Eastell R., Manhart M.D., Barton I.P., et al. Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate. greater increases in bone mineral density do not relate to greater decreases in fracture risk. J Clin Densitom 7 (2004) 255-261
67. Bjarnason N.H., Sarkar S., Duong T., Mitlak B., Delmas P.D., and Christiansen C. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12 (2001) 922-930
68. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17 (2002) 1-10
69. Riggs B.L., Hodgson S.F., O'Fallon W.M., Chao E.Y., Wahner H.W., Muhs J.M., et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Eng J Med 322 (1990) 802-809
70. Schnitzler C.M., Wing J.R., Gear K.A., and Robson H.J. Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis. Clin Orthop Relat Res (1990) 268-275
71. Meunier P.J., Sebert J.L., Reginster J.Y., Briancon D., Appelboom T., Netter P., et al. Fluoride salts are no better at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis. the FAVOStudy. Osteoporos Int 8 (1998) 4-12
72. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. Obstet Gynecol Surv 59 (2004) 526-527
73. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
74. Hui S.L., Slemenda C.W., and Johnston Jr. C.C. Age and bone mass as predictors of fracture in a prospective study. J Clin Invest 81 (1988) 1804-1809
75. Delmas P.D., Eastell R., Garnero P., Seibel M.J., Stepan J., and Committee of Scientific Advisors of the International Osteoporosis Foundation. The use of biochemical markers of bone turnover in osteoporosis. Osteoporos Int 11 suppl 6 (2000) S2-S17
76. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteoporos Int 11 suppl 6 (2000) S55-S65
77. Looker A.C., Bauer D.C., Chesnut III C.H., Gundberg C.M., Hochberg M.C., Klee G., et al. Clinical use of biochemical markers of bone remodeling. current status and future directions. Osteoporos Int 11 (2000) 467-480
78. Eastell R., Barton I., Hannon R.A., Chines A., Garnero P., and Delmas P.D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18 (2003) 1051-1056
79. Seibel M.J., Naganathan V., Barton I., and Grauer A. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19 (2004) 323-329
80. Reginster J.Y., Sarkar S., Zegels B., Henrotin Y., Bruyere O., Agnusdei D., et al. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34 (2004) 344-351
81. Garnero P., Mulleman D., Munoz F., Sornay-Rendu E., and Delmas P.D. Long-term variability of markers of bone turnover in postmenopausal women and implications for their clinical use. the OFELY study. J Bone Miner Res 18 (2003) 1789-1794
82. Garnero P., Dargent-Molina P., Hans D., Schott A.M., Breart G., Meunier P.J., et al. Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women?. The EPIDOS prospective study. Osteoporos Int 8 (1998) 563-569
83. Kanis J.A., Johnell O., Oden A., De Laet C., Jonsson B., and Dawson A. Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30 (2002) 251-258
84. Heaney R.P. Is the paradigm shifting?. Bone 33 (2003) 457-465
85. Ross P.D., Davis J.W., Epstein R.S., and Wasnich R.D. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 114 (1991) 919-923
86. Lindsay R., Silverman S.L., Cooper C., Hanley D.A., Barton I., Broy S.B., et al. Risk of new vertebral fracture in the year following a fracture. JAMA 285 (2001) 320-323
87. Brown J.P., and Josse R.G. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167 (2002) S1734
88. Cummings S.R., Black D.M., Thompson D.E., Applegate W.B., Barrett-Connor E., Musliner T.A., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
89. Siminoski K., Jiang G., Adachi J.D., Hanley D.A., Cline G., Ioannidis G., et al. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int 16 (2005) 403-410
90. Wehrli F.W., Hilaire L., Fernandez-Seara M., Gomberg B.R., Song H.K., Zemel B., et al. Quantitative magnetic resonance imaging in the calcaneus and femur of women with varying degrees of osteopenia and vertebral deformity status. J Bone Miner Res 17 (2002) 2265-2273
91. Link T.M., Vieth V., Stehling C., Lotter A., Beer A., Newitt D., et al. High-resolution MRI vs multislice spiral CT. which technique depicts the trabecular bone structure best?. Eur Radiol 13 (2003) 663-671